Revitalizing Innovation

Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.

Authors

Institutions

Publication Details

Journal
JACC Basic to Translational Science
Published
2024-10-16
DOI
https://doi.org/10.1016/j.jacbts.2024.08.006
Primary Topic
Private Equity and Venture Capital
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Revitalizing Innovation

Juan F. Granada, Louis Cannon, Partha Sardar
JACC Basic to Translational Science
Private Equity and Venture Capital
article

Revitalizing Innovation

Juan F. Granada, Louis Cannon, Partha Sardar
article en

Abstract

Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.

JACC Basic to Translational ScienceVol. 9(12)
NewYork–Presbyterian Hospital (US), Cardiac And Vascular Research Center Of Northern Michigan (US), Cardiovascular Research Foundation (US), Columbia University (US)
Openalex Percentile: Top 70%
Private Equity and Venture Capital
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.